WO2025203012 - KRAS G12C INHIBITOR FOR USE FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER
National phase entry is expected:
Publication Number
WO/2025/203012
Publication Date
02.10.2025
International Application No.
PCT/IB2025/090001
International Filing Date
27.03.2025
Title **
[English]
KRAS G12C INHIBITOR FOR USE FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER
[French]
INHIBITEUR DE KRAS G12C DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DU CANCER DU POUMON NON À PETITES CELLULES
Applicants **
NOVARTIS AG
Inventors
BITTON, Rafael Caparica
CUI, Xiaoming
LOBETTI BODONI, Chiara
YOVINE, Alejandro Javier
Priority Data
63/570,531
27.03.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2512 | |
| EPO | Filing, Examination, Granting | 15650 | |
| Japan | Filing, Examination, Granting | 2607 | |
| South Korea | Filing, Examination, Granting | 2925 | |
| USA | Filing, Examination, Granting | 7140 |
Total:
30,834
Contact Us
Abstract[English]
The present invention relates to a method of treating non-small cell lung cancer (NSCLC) which harbors a KRAS G12C mutation, wherein the method comprises the administration of a therapeutically effective amount of KRAS G12C inhibitor 1-{6-[(4M)-4-(5-Chloro-6-methyl-5 1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one (Compound A), or a pharmaceutically acceptable salt, solvate or hydrate thereof, a therapeutically effective amount of pembrolizumab, a therapeutically effective amount of pemetrexed and a therapeutically effective amount of platinum therapy; in particular the present invention relates to a method of treating NSCLC wherein the NSCLC expresses at least 1% PD-L1 according to the tumor proportion score (TPS), more particularly wherein the NSCLC expresses less than 50% PD-L1 according to the tumor proportion score (TPS), more particularly wherein the NSCLC expresses PD-L1 1- 49% according to the tumor proportion score (TPS), even more particularly wherein the NSCLC expresses <1% PD-L1 according to the tumor proportion score (TPS).[French]
La présente invention concerne une méthode de traitement du cancer du poumon non à petites cellules (NSCLC) qui héberge une mutation KRAS G12C. La méthode consiste à administrer une quantité thérapeutiquement efficace d'inhibiteur de KRAS G12C 1-6-[(4M)-4-(5-chloro-6-méthyl-5 1H-indazol-4-yl)-5-méthyl-3-(1-méthyl-1 H-indazol-5-yl)-1 H-pyrazol-1-yl]-2-azaspiro [3,3] heptan-2-yl}prop-2-en-1-one (composé A), ou un sel, solvate ou hydrate pharmaceutiquement acceptable de celui-ci, une quantité thérapeutiquement efficace de pembrolizumab, une quantité thérapeutiquement efficace de pémétrexed et une quantité thérapeutiquement efficace de thérapie au platine. En particulier, la présente invention concerne une méthode de traitement du NSCLC, le NSCLC exprimant au moins 1 % de PD-L1 selon le score de proportion tumorale (TPS), plus particulièrement le NSCLC exprimant moins de 50 % de PD-L1 selon le score de proportion tumorale (TPS), plus particulièrement le NSCLC exprimant PD-L1 de 1 à 49 % selon le score de proportion tumorale (TPS), encore plus particulièrement le NSCLC exprimant moins de 1 % de PD-L1 selon le score de proportion tumorale (TPS).